Status:

WITHDRAWN

TrueRelief Efficacy for Supraspinatus Tendonitis

Lead Sponsor:

Weill Medical College of Cornell University

Collaborating Sponsors:

TrueRelief, LLC

Conditions:

Supraspinatus Tendinitis

Shoulder Pain

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

The investigators hypothesize that TrueRelief will result in improved outcomes for patients with shoulder pain compared to those receiving the sham TrueRelief treatment. Also, it is likely that those ...

Detailed Description

Supraspinatus tendonitis (SST) is a common source of shoulder pain that primary care, sports medicine, and orthopedic surgeons regularly manage. TrueRelief's FDA-cleared device, called TrueRelief 1250...

Eligibility Criteria

Inclusion

  • Those with shoulder pain of recent onset (\<3 months)
  • Those with supraspinatus tendonitis only (see exclusion criteria below)
  • Those whose physical examination meets either criteria below:
  • Positive impingement tests
  • At least two of:
  • Jobe
  • Modified Jobe
  • Hawkins-Kennedy
  • Neer
  • Painful arc:
  • Painful arc at 70-120 degrees abduction and/or
  • Painful arc at 70-120 degrees flexion
  • Pain with resisted abduction and/or external rotation
  • Those between the ages of 18 and 65
  • Those willing and able to sign consent

Exclusion

  • Those who have had ipsilateral shoulder surgery involving the supraspinatus muscle
  • Those who have experienced a fracture or avulsion fracture of any element of the shoulder or forequarter area (rib cage, clavicle, or humerus)
  • Those with full-thickness rotator cuff tear
  • Those with a long head of biceps rupture
  • Those with shoulder pathology other than SST (ex: glenohumeral joint (GHJ) arthritis, adhesive capsulitis, labral tear). However, ACJ arthritis can be admitted since this is a very common comorbidity.
  • Those with comorbidities that may confound the outcome, such as:
  • Diabetes (either type I or type II)
  • Auto-inflammatory diseases
  • Auto-immune diseases
  • Connective tissue disorders (Ehlers Danlos Syndrome)
  • Those with demand type pacemakers
  • Pregnancy

Key Trial Info

Start Date :

May 4 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2023

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT05184985

Start Date

May 4 2022

End Date

June 1 2023

Last Update

July 3 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

New York Presbyterian/Weill Cornell Medical Center Rehabilitation Medicine

New York, New York, United States, 10065